Patients with oligoprogressive metastatic castration-resistant prostate cancer who have detectable circulating tumor DNA (ctDNA) before stereotactic body radiotherapy (SBRT) face a significantly higher risk of rapid disease progression, according to a secondary analysis published in JAMA Network Open on November 11, 2026.
The study, which examined 77 patients from the Targeted Radiotherapy in Androgen-Suppressed Prostate Cancer Patients (TRAP) trial, found that ctDNA status serves as a critical indicator of how patients may respond to targeted radiation. Researchers observed that those without detectable ctDNA before treatment experienced longer periods of disease control.
The trial enrolled 81 patients with castration-resistant prostate cancer and two or fewer progressing metastases between October 17, 2018, and February 1, 2023. Patients had a rising prostate-specific antigen level after at least six months of abiraterone acetate or enzalutamide and received SBRT at 30 Gy in five fractions while continuing androgen receptor pathway inhibitor therapy. The median follow-up was 24.5 months.
The analysis revealed that 19 of the 77 patients (24.7%) tested positive for ctDNA prior to undergoing SBRT. These patients showed a median progression-free survival of only 3.0 months, compared with 7.8 months for those who tested negative, a difference that reached statistical significance (p=0.003), according to the study data. The association remained significant after researchers accounted for other clinical factors, including age, prostate-specific antigen levels, previous chemotherapy and the location of the treated tumour.

| Patient Group | Median Progression-Free Survival | 6-Month Survival Rate |
|---|---|---|
| ctDNA-positive | 3.0 months | 21.1% |
| ctDNA-negative | 7.8 months | 58.3% |
Stereotactic body radiotherapy delivers highly focused radiation to specific tumor sites, allowing patients to continue their existing hormone-based treatments. Because patients in the trial rarely experienced progression at the specific sites treated with SBRT, researchers suggested that the earlier relapses seen in ctDNA-positive patients likely reflect active metastases that were not visible on standard imaging.
“These findings suggest that a simple blood test could give us valuable additional information about how advanced prostate cancer is behaving, beyond what we can see on scans,” said Alison Reid, a consultant medical oncologist at The Royal Marsden NHS Foundation Trust and chief investigator of the TRAP trial.
While the study indicates that pretreatment ctDNA levels could help clinicians identify which patients are most likely to benefit from SBRT, the researchers cautioned that the trial was nonrandomized. Investigators are now looking toward future studies to determine if this blood test can formally guide clinical decision-making.
“These findings suggest that radiotherapy may be considered when ctDNA findings are negative; when ctDNA is detected, an alternative systemic treatment should be used,” said Gerhardt Attard, director of the University College London (UCL) Cancer Institute.
“Although more research is needed before this test can be used to guide treatment decisions, our findings are an important step towards understanding which patients may benefit most from targeted radiotherapy and how we could better personalise treatment for men with advanced prostate cancer,” Reid said.
Keep reading